Drug intelligence / Profile preview

fusidic acid + tacrolimus

Development stage: Preclinical
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Topical

Overview

A combination of fusidic acid, a topical antibacterial agent, and tacrolimus, a calcineurin inhibitor immunosuppressant. This combination has been studied for the treatment of atopic dermatitis. Tacrolimus works by inhibiting T-lymphocyte activation and inflammatory cytokine production, while fusidic acid prevents bacterial growth, primarily by interfering with bacterial protein synthesis. Studies have indicated that complementary fusidic acid had no additional benefit compared with tacrolimus alone in treating atopic dermatitis.

Targets

CN (Calcineurin)EF-G (Elongation factor G 1, mitochondrial)

Beyond the preview

Go deeper on fusidic acid + tacrolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fusidic acid + tacrolimus.

Explore the full profile